Impact Factor: 4.8
Citescore: 6.7
All metrics >>
Highlighted Articles
Online First
Original research:
Low-dose lenvatinib and anti-programmed cell death protein-1 combination therapy in patients with heavily pre-treated recurrent ovarian and endometrial cancer: a pilot study24 April 2024
Original research:
Circulating tumor DNA as a biomarker for predicting progression-free survival and overall survival in patients with epithelial ovarian cancer: a systematic review and meta-analysis24 April 2024
Clinical trial:
Biomarker-driven targeted therapy in patients with recurrent platinum-resistant epithelial ovarian cancer (BRIGHT): protocol for an open-label, multicenter, umbrella study24 April 2024
Most Read Articles
Original research:
ESGO/ESTRO/ESP Guidelines for the management of patients with cervical cancer – Update 2023*1 May 2023
Original research:
Endometrial cancer after endometrial ablation: a systematic review5 December 2022
Original research:
ESGO/ESTRO/ESP Guidelines for the management of patients with cervical cancer – Update 2023*1 February 2024
Current Issue
Review:
Mirvetuximab soravtansine-gynx: first antibody/antigen-drug conjugate (ADC) in advanced or recurrent ovarian cancer1 April 2024
Society statement:
European Society of Gynaecological Oncology expanded quality indicators and accreditation for cervical cancer management1 April 2024
Original research:
Intraepithelial tumor-infiltrating lymphocytes shape loco-regional PET/CT spread of locally advanced cervical cancer1 April 2024
Original research:
Malnutrition is associated with poor survival in women receiving radiotherapy for cervical cancer1 April 2024
IJGC Zoom Journal Club
Mirvetuximab soravtansine-gynx: first antibody/antigen-drug conjugate (ADC) in advanced or recurrent ovarian cancer
Join Editor in Chief Pedro Ramirez, David Viveros, René Pareja, and the IJGC Editorial Fellows in a lively and entertaining discussion over Zoom of the lead article in IJGC's April 2024 issue.
Find out more